Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.New York State Department of Health (NYS DOH) has granted clinical laboratory permission to the Rosetta Genomics, a provider of microRNA-based molecular diagnostic tests.
Subscribe to our email newsletter
The permission will allow patients and physicians residing in the State of New York to attain access to the company’s miRview mets, miRview squamous, and miRview meso tests.
The company is now working to gain NYS DOH approval for the first of its second generation tests miRview mets2.
Rosetta Genomics president and CEO Kenneth Berlin said the microRNA-based diagnostic products are now available to residents of all 50 US states including NewYork.
"Receipt of this permit confirms that Rosetta’s CAP-accredited, CLIA-certified laboratory meets the strict requirements of New York State for quality-controlled, accurate and reliable clinical laboratory services.
"Rosetta Genomics has made considerable investment in the development of our proprietary microRNA technology platform, and we have a robust portfolio of diagnostic tests on the market, nearing commercial launch and in development and we look forward to provide the benefits of these powerful diagnostic products to a growing number of clinicians and patients," Berlin said.